Navigation Links
CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price
Date:8/26/2008

WOBURN, Mass., Aug. 26 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) announces the release of the Maestro(TM) EX In Vivo Imaging System. The new system incorporates CRi's state-of-the-art FLEX technology and becomes the entry-level instrument of choice for in vivo fluorescence imaging.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080826/NETU054 )

FLEX technology represents a significant advancement of CRi's unique solid-state tunable optics that for the first time enables both broad- and narrow-band spectral imaging at the click of a button. The user can select high optical throughput for reduced experiment times or increased spectral resolution for enhanced separation of similar fluorescent labels.

Accurate spectral detection is essential for quantitative signal unmixing. Patent-pending Maestro software tools complement the improved optical capabilities of the Maestro EX by ensuring accurate and automated characterization of fluorescent signals in spectrally complex samples. Dynamic Contrast Enhancement (DyCE(TM)) is available as an accessory. DyCE is a revolutionary all-optical anatomic imaging solution for mice that also helps eliminate signals from non-specific binding in much less time than conventional means-by as much as 90% less time.

"You will be able to detect and measure more markers in your mouse model and resolve even extremely closely spaced and overlapping emission signals." explains James Mansfield, Director of Multispectral Imaging Systems at CRi.

The Maestro EX enables more precise detection and quantitation of molecular probes in live animals and complements the automated high-throughput Maestro 2 imaging system, by providing comparable imaging performance in a design intended for lower-throughput manual operation.

By providing unprecedented accuracy, sensitivity, and flexibility, along with powerful and intuitive software, the Maestro EX solidifies CRi's reputation as the industry's leading provider of in vivo fluorescence imaging systems.

Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable our customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.

With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility. We are able to rapidly design and manufacture system- level solutions for a variety of growing market applications.

Visit http://www.cri-inc.com/maestro-pr to find out more about the Maestro EX system.

For more information visit our website at http://www.cri-inc.com or contact:

Ross Nakatsuji

CRi Marketing/Sales Group Leader

35-B Cabot Road, Woburn, MA 01801 USA

(P) 1-781-935-9099, extension 177, (C) 1-781-405-4000,

(E) rnakatsuji@cri-inc.com


'/>"/>
SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  As people age, it ... multitude of recommended screenings and tests that are linked ... priority. However, for the majority of aging individuals, hearing ... planning. For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ...
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
Breaking Medicine Technology:
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. ... Kybella® to his medical and surgical expertise. Technically known as deoxycholic acid or ... used as a non-surgical alternative for reduction of fat below the chin (aka ...
(Date:2/6/2016)... , ... February 06, 2016 , ... Shark Finds ... announce the launch of a new DRTV campaign with Belly Bands. , Having a ... everything from sprays to puppy pads and find nothing works, get Belly Bands, ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... the availability of the company's lighter, sleeker next generation LYNX VR Indoor Trainer ... , Improvements in design and manufacturing not only reduce the weight of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for ... kids and adults with muscular dystrophy, ALS and related diseases that severely limit ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... After years ... General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief ... Hospital. He successfully completed his first three-year term as chief and began a second ...
Breaking Medicine News(10 mins):